Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (August 2021)
24 slides from Infusystems's investor presentation, Aug 12, 2021
Slide 1: Enabling Continuity of Care for Patients, From the Clinic to Their Home
rs Enabling Continuity of Car r Patients, From the Clinic to Their Home Investor Presentation AUGUST 12, 2021 | (NYSE American: INFU)
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Non-GAAP Measures Certain statements contained in this presentation are forward-looking statements ‘This presentation contains information prepared in conformity with GAAP within the meaning of Section 27A ofthe Securities Act
Slide 3: Investment Highlights
Investment Highlights 2021 Revenue Guidance $107-$110M Double-digitgrowth Providing best-in-class $10B U.S. and Canada __ Gaining market Strategy to continue through two proven _durable medical Home DME market; _ share by delivering leveraging DME business platforms: equipmentand growth driven by “t
Slide 4: A leading provider of equipment and services
@ Aleading provider of equipmentand services with a U.S. and Canada ear history, perfected model in Oncologyand now expandinginto multiple therapies @ seven major service areas in the U.S. and Canada with over 340 employees @® National scale, serving ©@ Third-party payer contracts covering nearly 95
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $36.3M (37%) DURABLE MEDICAL EQUIPMENT (DME) SUPPORT SERVICES Equipment and consumable sales/lease to hospitals, clinics and home infusion providers Total 2020 Revenue: $97.4 Million ITS $61.1M (63%)
Slide 6: Well-Diversified & Strategic Payer Relationships
Well-Diversified & Strategic Payer Relationships Percentage of Cash Collected by Payer 2020 Medicaid: 1.3% Uninsured: 0.3% 6,500+ Direct Pay Hospital and Alternate Site Customers Hospital/Alternate aite Direct Pays 47-73 Commercial Payer: 50.7% No Single Payer Greater Than 11.0% on |ART. TRUSTED. (I
Slide 7: DME Platform
DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model Source Devices Le Device Repair & —— Maintenance © Pump rentals and VAR sales (new devices) @ Broker/trader sales (used devices) @ Biomedical service and repair @ Direct payer model: INFU is paid directly by the hospital/cl
Slide 8: ITS Platform
ITS Platform Unique and Scalable, High-Margin, High-Service Model Device Repair & Maintenance © supply medical equipment and proprietary consumables for outpatient care @ Hospital, clinician and patient customer service @ Third-party payer model: INFU is paid by the patient’s medical insurance provi
Slide 9: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based on Unique Focus, National Scale and Established Payer Network Clinical Car InfuSystem 24/7 Nursing Team Pro nuous patient support to minimize: ‘outcomes. Our workflow patient and clinical team communication to ‘maintain peace of mind. Qualit
Slide 10: Growth Strategy of ITS Platform
Growth Strategy of ITS Platform ‘Adding New High-Margin Therapy Segments ee Go-to-Market Growth/Traction Established Strategy ‘Oncology Pain Management Negative Pressure Wound Therapy lymphedema Therapy Future Therapies - $97.4 million 2020 revenue ‘Over $900 million current realizable opportunities
Slide 11: Highly Scalable Existing Infrastructure
Highly Scalable Existing Infrastructure Foundation Builtin Oncology: Leveraged It Multiple Times (Pain, NPWT, lymphedema) Oncology Pain Management NPWT Lymphedema Offices and Logistics Future Therapies 34 Years of Experience, + Full Coverage of the U.S. Know-How and Reputation and Canada (MI, KS, CA
Slide 12: ITS Model: Platform Proven in Oncology
ITS Model: Platform Proven in Oncology InfuSystem ITS Value Propo: Opportunity: Oncology Home Treatment * Large capital expense for clinics in addition to maintenance and nightly triage + Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient Treatment
Slide 13: Second Quarter Financial Results
Second Quarter Financial Results Net Revenue Net Income AEBITDA” Op Cash Flow (2) See Appendix A. 2021 2020 2021 2020 2021 2020 2021 2020 EE sm ee Bso.sm ME s4.im EE Ss.s EE <5 HEE $6.1m ME $3.7
Slide 14: First Half Financial Results
First Half Financial Results Net Revenue 202. ED $49.30 2020 ne $47.51 $1.5M Net Incom 2021 Hl e 2020 MM S3.7™ AEBITDA” 2021 EEE $12.0 2020 ME si2.cv Op Cash 2021 MEE ss.2u e Flow 2020 MEE s4.3m (3) See Aopen.
Slide 15: Full Year Financial Results
Full Year Financial Results 2020 nn $97.41 Net Revenue 2019 es S211 2020 ME $17.3 Net Incom etincome 2019 §$1.4M a 2020 MEN s26.4m AEBIDDA 2019 MEE sis.am 2020 MEE $20.3 Op Cash Flow 15 mM s13.0m (a)SeeAopendic 4 Custom
Slide 16: Financial Trend & Current 2021 Guidance
Financial Trend & Current 2021 Guidance $120.00 Net Revenues() & AEBITDA) Seeo= San 550 325 320 5 i 2 : so g 3 + $0 20178 20188 20198 20208 200 TE hontai —Bb~ AmaaroA SE anoNeRewne ~~ aro Araron Notes: 1. 2017 consolidstedrevenuns have been ajustedtoeflet the efecto the adoption of ASC i201. 2 Seeap
Slide 17: Financial Trend & Current Targets
Financial Trend & Current Targets Cash Flows From Operations 240 $19.0-$220 | 245% 0% 5% 10% 20.0% 18.5% uoKs) 37.0% 15.9% 18.0% 23% | sn0%
Slide 18: Recent Accomplishments
Recent Accomplishments Launched Lymphedema Therapy in ITS platform via joint agreement with Bio Compression Systems, Inc. — June 2021 Acquisition and integration of two biomedical services companies; enabling entry into acute care service market — Early 2021 Raised annual revenue, adjusted EBITDA an
Slide 19: Corporate Priorities
Corporate Priorities oO Eniedentyaomun omen peree emieeceetenoemers OO} Expand Pain Management and NPWT market share OO Begin onboarding new customers for new lymphedema Therapy in 2022 - 2023 | Announce new contri th health plan and hath car ayers | Enter into new partnerships to develop additional
Slide 20: Seasoned Industry Experience
20 Seasoned Industry Experience, Includin Pharmaceutical, Health Care, Life Sciences, Medical Device, Automotive OEM, Public Accounting, Military, Retail, Consumer Brands, Digital Advertising, Consulting & High-Tech siden ‘trae Ofee 1 Chef operating Ofcer
Slide 21: Summary
Summary care from the clinic into the home, driving double-digit > Two proven platforms that enable the delivery of patient ™ revenue, cash flow growth and accelerating profit TQ Market opportunities driven by rising health care costs, an aging population, medical innovation, patient satisfaction an
Slide 22: Questions & Answers
SAFE, SMART. TRUSTED Questions & Answers
Slide 23: Appendix A: GAAP to Non-GAAP Reconciliation
Appen ix A caapto now-caar reconciliation [NETINCOME (L088) TO ADJUSTED EBITOA: Ainthousands) 2017 {GAAP net income (loss) (20,707) Adjustments: Interest expense 4.332 Income tax provision (benefit) 15450 Depreciation 6.963 Asset impairment 993 ‘Amortization 5,560 ‘Non-GAAP EBITDA $9591 Stock compen
Slide 24: Appendix B: Select Balance Sheet Data
APPeNndix B select Balance sheet Data inssonh Decemberst, December, June 30, Cash and Cash Equivalents S$ 2647 $9,648 $164 Available Liquidity 21,258 19,685, 42,161 dA orn 2,893 6,549 6,182 Medical Equipment, Net 33,225 35,611 35,401 Total Assets 79,224 96,991 95,997 Total Debt 38,377 38,801 32,460
InfuSystem Holdings — Investor Presentation (August 2021) on 6ix